Although ERα positive malignancies are conventionally associated with improved prognosis and sensitivity to AET, exploitation of ERα as a treatment strategy has not gained wide acceptance in ovarian cancer care despite known expression of the receptor [9], [10]. The gene discussed is ESR1; the disease is ovarian carcinoma.